上海科华生物工程股份有限公司 信息披露管理制度 （2023 年 8 月修订） 第一章 总则 第一条 为规范上海科华生物工程股份有限公司（以下简称"公司"）信息 披露的管理，提高公司信息披露的质量，保证公司信息披露的及时性、公平性、 真实性、准确性和完整性，杜绝泄露内幕信息、内幕交易等违法违规行为，根据 《中华人民共和国公司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司信息披露管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交 易所上市公司自律监管指引第 1 号——主板上市公司规范运作》以及中国证监会 发布的信息披露的内容与格式准则等法律、法规和规范性文件的规定，并结合公 司具体情况，特制定本制度。 第二条 本制度所称"信息披露"是指将可能对公司股票、债券及其衍生品 种交易价格产生重大影响而投资者尚未得知的重大信息以及证券监管机构要求 披露的信息，并在规定的时间内、在规定的媒体上、以规定的方式向社会公众公 布，并按规定送达证券监管机构和深圳证券交易所。 第二章 信息披露的基本原则 第三条 信息披露义务人应当及时依法履行信息披露义务，披露的信息应当 真实、准确、完整，简明清晰、通俗易 ...

上海科华生物工程股份有限公司 第一章 总则 第一条 为了加强上海科华生物工程股份有限公司（以下简称"公司"）与 投资者之间的沟通，增进投资者对公司的了解，倡导理性投资，促进公司治理 结构的改善，提升公司投资价值，根据《中华人民共和国公司法》、《中华人民共 和国证券法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》等相关法律、法规及规范性文件和《上海科华生物工程股份有限公司章 程》的规定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者 对公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 投资者关系管理制度 (2023 年 8 月修订) 第二章 投资者关系管理的基本原则 第三条 投资者关系管理工作的基本原则是： （一）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的 基础上开展，符合法律、法规、规章及规范性文件、行业规范和自律规则、公 司内部规章制度，以及行业普遍遵守的道德规范和行为准则； （二 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：002022 | 证券简称：科华生物 | 公告编号：2023-077 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 上海科华生物工程股份有限公司 关于产品获得医疗器械注册证的公告 特此公告。 上海科华生物工程股份有限公司董事会 2023 年 8 月 12 日 近日，上海科华生物工程股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的《医疗器械注册证》（体外诊断试剂）。具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 适用范围/预期用途 | | --- | --- | --- | --- | --- | | 1 | 乙型肝炎病毒核酸测定 | 国械注准 | 2023 年 8 月 9 日 | 本试剂盒用于定量检 测人血清或血浆样本 | | | 试剂盒（PCR-荧光探针 | 20233401120 | 至 | | | | 法） | | 2028 年 8 月 8 日 | 中的乙型肝炎病毒核 | | | | | | ...

证券代码：002022 证券简称：科华生物 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|------------------------|------------------------------------------|-------------------| | | | | 编号：2023005 | | 投资者关系活动 | √特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 财通证券 邢卓 | | | | 人员姓名 | 宁涌富基金 韩洲枫 | | | | 时间 | 2023 年 6 月 13 日下午 | 14:30 | | | 地点 | 公司会议室 | | | | 上市公司接待人 | | | | | 员姓名 | 龙 | | | | | | | | | | 为与 ...

证券代码：002022 证券简称：科华生物 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------------|-------------------------|------------------------------------------| | | | 编号：2023004 | | 投资者关系活动 | √特定对象调研 | | | 类别 | □ 媒体采访 | | | | □ 新闻发布会 □ | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | | | 人员姓名 | 江海证券 徐圣钧、任沐昕 | | | 时间 | 2023 年 06 月 06 日上午 | | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | | | | | | | | | 为与会人员交流。 | | | | 一、公司介绍 | | | | 科华生物成立于 | 年，国内首家深交所中小板 IVD 上市 | | | | | | 投资者关系活动 | | | | 主要内容介绍 | | ...

证券代码：002022 证券简称：科华生物 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------| | | | 编号：2023003 | | 投资者关系活动 | √特定对象调研 | | | 类别 | □ 媒体采访 | | | | □ 新闻发布会 □ | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | | | | 信达证券 王明路 | | | 人员姓名 | | | | 时间 | 2023 年 05 月 18 日下午 | | | 地点 | 公司会议室 | | | 上市公司接待人 | | | | | | | | 员姓名 | | | | | | | | | 为与会人员交流。 | | | | 一、公司介绍 | | | | 科华生物成立于 | 年，国内首家深交所中小板 IVD 上市 | | | | | | 投资者关系活动 | | ...

证券代码：002022 证券简称：科华生物 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 投资者关系活动记录表 | --- | --- | |----------------|------------------------------| | 投资者关系活动 | √特定对象调研 | | 类别 | □ 媒体采访 | | | □ 新闻发布会 | | | □ 现场参观 | | | □ 其他 | | 参与单位名称及 | 太平洋证券 张健 | | 人员姓名 | 太平洋证券 王献楠 | | 时间 | 2023 年 05 月 11 日上午 | | 地点 | 公司办公室 | | 上市公司接待人 | | | 员姓名 | 龙 | | | | | | | | | | | | 下是本次交流的主要内容汇总： | | | 一、公司介绍 | | 投资者关系活动 | 科华生物成立于 | | 主要内容介绍 | | | | | | | | | | | | | 司产品覆盖全国 30 | | | | | | 时出口至海外 100 | | --- | |----------------------------------- ...

上海科华生物工程股份有限公司 2023 年第一季度报告 | 证券代码：002022 | 证券简称：科华生物 | | --- | --- | | 债券代码：128124 | 公告编号：2023-044 债券简称：科华转债 | 上海科华生物工程股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减（%） | | | --- | --- | --- | --- | --- | | 营业收入（元） | 833,147,693.69 | 420,497,071.93 | ...

Financial Performance - The company's operating revenue for 2022 was ¥6,969,862,627.72, representing a 43.58% increase compared to ¥4,268,011,808.72 in 2021[20] - The net profit attributable to shareholders for 2022 was ¥970,845,080.02, which is a 14.16% increase from ¥721,016,662.06 in 2021[20] - The net cash flow from operating activities reached ¥2,153,632,187.55, marking a significant increase of 99.55% compared to ¥775,342,174.21 in the previous year[20] - Basic earnings per share for 2022 were ¥1.8878, up 14.09% from ¥1.4026 in 2021[20] - The net profit after deducting non-recurring gains and losses was ¥952,357,688.19, reflecting a 13.88% increase from ¥704,501,000.58 in 2021[20] - Total assets increased to ¥8,813,157,013.32, up 26.71% from ¥6,955,215,549.19[21] - Net assets attributable to shareholders rose to ¥4,814,922,149.78, reflecting a 24.34% increase from ¥3,872,397,866.89[21] Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥6 per 10 shares to all shareholders, with no bonus shares or capital reserve conversion[4] - The proposed cash dividend for the 2022 fiscal year is ¥6 per 10 shares, with no stock dividends or capital reserve transfers planned[152] Market and Industry Insights - The company operates in the in vitro diagnostic market, which is rapidly growing due to factors like aging population and increased healthcare spending[33][34] - The global in vitro diagnostics (IVD) market size was $67.11 billion in 2019 and is projected to reach $91.09 billion by 2027, with a CAGR of 4.8% from 2020 to 2027[35] - China's IVD market grew from approximately RMB 42.75 billion in 2015 to about RMB 80.57 billion in 2019, with a CAGR of 17.2%[36] - By 2030, China's IVD market is expected to reach RMB 288.15 billion, capturing 33.2% of the global market share[36] Product Development and R&D - The company has over 100 projects in different stages of research and development, with more than 260 approved reagents and instruments by the National Medical Products Administration[44] - The company emphasizes R&D investment, having undertaken over 30 major national science and technology projects[44] - The company continues to invest in R&D, focusing on new product development across multiple product lines, including biochemical and molecular diagnostics[48] - Research and development expenses increased by 68.71% to ¥250,493,757.83 in 2022, up from ¥148,472,181.49 in 2021, reflecting a significant increase in R&D investment[64] Sales and Revenue Breakdown - The company's self-produced products accounted for 77.34% of total revenue, with a significant growth of 62.19% year-on-year[53] - Domestic sales contributed 90.48% of total revenue, showing a substantial increase of 68.62% compared to 2021[53] - The total sales volume of self-produced diagnostic reagents reached 13,996,293 boxes in 2022, a year-on-year increase of 58.49% compared to 8,830,845 boxes in 2021[56] - The sales volume of self-produced medical instruments surged to 52,157 units, marking a 159.59% increase from 20,092 units in 2021[56] Corporate Governance and Management - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management to ensure the achievement of development strategies and operational goals[103] - The board of directors consists of seven members, including four independent directors, ensuring compliance with legal and regulatory requirements[102] - The company has implemented a performance evaluation system for senior management, with a new assessment method established for 2022[141] - The company has maintained a stable management structure with no significant changes in senior management during the reporting period[112] Risk Management and Compliance - The company has identified potential risks in its future operations, which are detailed in the management discussion section of the report[4] - The company faces risks from regulatory changes in the in vitro diagnostics industry, which could adversely affect its operations[95] - The company acknowledges the long development cycle for new products, which typically takes 3-5 years, and is implementing measures to mitigate R&D risks[96] - The company has established departments to ensure timely registration of products in domestic and international markets, reducing registration risks[97] Financial Audit and Reporting - The company’s financial statements have been audited by Da Hua Certified Public Accountants[19] - The company has appointed Dahua Accounting Firm for the 2022 annual audit, with an audit fee of ¥2,120,000, marking the first year of service[183] - The internal control audit report for Kehua Bio-engineering Co., Ltd. indicates effective financial reporting internal controls as of December 31, 2022, with a standard unqualified opinion[164] Employee and Compensation Information - The total number of employees at the end of the reporting period is 2,709, with 921 in the parent company and 1,788 in major subsidiaries[143] - Total pre-tax compensation for the company's directors, supervisors, and senior management during the reporting period amounted to CNY 552.03 million[129] - The company has implemented a performance-oriented compensation management system to enhance employee development and satisfaction[169] Strategic Initiatives and Future Plans - The company plans to focus on cardiovascular health, liver disease, kidney disease, infectious diseases, tumors, reproductive health, and maternal and child health, aiming for comprehensive disease management[91] - The company aims to expand into the in vitro diagnostic reagent raw material market, ensuring strategic safety for product development and production[92] - The company is expanding its drug metabolism and genetic disease application areas through the development of new drug gene testing kits, with several products expected to be registered in 2023 and 2024[68] Legal Matters - The company reported a total litigation amount of approximately ¥1,050,433,000 related to arbitration with Tianlong Technology Co., Ltd. and Suzhou Tianlong Biotechnology Co., Ltd.[187] - The company has not faced any significant penalties or rectification measures during the reporting period[189]